Alzheimer’s Blood Tests and Long-Term Care Insurance: What Consumers Must Know Before Testing

Alzheimer’s Blood Tests and Long-Term Care Insurance are becoming closely linked as medical innovation advances faster than insurance underwriting standards. Blood-based Alzheimer’s tests and genetic screening can provide valuable clinical insight—but they can also permanently affect your ability to qualify for long-term care insurance (LTCi).

If you are considering an Alzheimer’s blood test or genetic testing for dementia, the order in which you take action matters. In many cases, securing long-term care insurance before any dementia-related testing is crucial.

This article explains how Alzheimer’s blood tests work, how genetic testing fits into dementia risk, and how insurers evaluate this information when determining eligibility.

Alzheimer’s Blood Tests and Long-Term Care Insurance: Why Timing Matters

Alzheimer’s Blood Tests and Long-Term Care Insurance intersect at one critical point: medical records.

Once dementia-related testing is ordered, results—and even the reason for testing—often become part of your permanent medical record. Long-term care insurance underwriters rely heavily on those records when assessing future risk.

From an underwriting perspective:

• Alzheimer’s blood testing suggests possible cognitive concerns

• Abnormal or uncertain results often lead to specialist referrals

• Documentation may include terms such as “memory impairment,” “MCI,” or “cognitive decline”

Even without a formal Alzheimer’s diagnosis, these notations can make qualifying for coverage difficult or impossible.

Consumer rule of thumb:
👉 Apply for long-term care insurance first. Test later.

Alzheimer’s Blood Tests and Long-Term Care Insurance: What Tests Are Available

Alzheimer’s blood tests measure biological markers associated with Alzheimer’s disease—most commonly amyloid beta (Aβ) and phosphorylated tau (p-tau). These biomarkers reflect changes in the brain linked to Alzheimer’s pathology.

FDA-cleared Alzheimer’s blood tests

Recent FDA-cleared tests are designed to help clinicians determine whether Alzheimer’s-related brain changes are likely in symptomatic individuals. These tests:

• Are not diagnostic on their own

• Often trigger additional testing such as PET scans or neurological evaluations

• Are intended to support, not replace, clinical judgment

Commercial and CLIA laboratory tests

Several major laboratories offer Alzheimer’s biomarker blood tests under CLIA regulations. These tests are widely marketed and accessible but still:

• Enter the medical record

• Prompt follow-up care

• Raise underwriting red flags for long-term care insurance

Key point: Regardless of FDA status, once Alzheimer’s blood testing is documented, it can affect insurability.

Alzheimer’s Blood Tests and Long-Term Care Insurance: The Role of Genetic Testing

Genetic testing for dementia is another area where Alzheimer’s Blood Tests and Long-Term Care Insurance overlap.

APOE genetic testing

• APOE ε4 increases Alzheimer’s risk but does not predict who will develop the disease

• Many people with APOE ε4 never develop dementia

• Testing is generally not recommended for routine screening

Rare hereditary Alzheimer’s genes

In families with early-onset dementia, testing for specific genetic mutations may be considered. These tests are uncommon and typically involve genetic counseling.

Why genetic testing matters for insurance

The federal Genetic Information Nondiscrimination Act (GINA) protects consumers for health insurance, but long-term care insurance is not covered under GINA. This means genetic test results can legally be used in LTCi underwriting if documented.

Alzheimer’s Blood Tests and Long-Term Care Insurance: How Underwriters Review Medical Records

Long-term care insurance underwriting focuses on future claim risk. Underwriters evaluate:

Health application and interview

Applications often include detailed health histories and cognitive screening questions, especially for older applicants.

Prescription history and databases

Prescription use and shared underwriting databases may reveal cognitive-related medications or evaluations.

Medical records (the most important factor)

Insurers may request physician notes or electronic health records showing:

• Memory complaints

• Cognitive testing

• Neurology referrals

• Alzheimer’s blood test results

• Diagnostic codes or assessment impressions

MIB (Medical Information Bureau)

MIB collects coded information used by insurers during underwriting, including long-term care insurers, with consumer authorization.

Once dementia-related testing appears in these records, underwriting decisions change—often permanently.

Alzheimer’s Blood Tests and Long-Term Care Insurance: How Testing Can Affect Eligibility

Alzheimer’s blood testing can impact insurability in several ways:

• A positive biomarker result may be treated as evidence of early Alzheimer’s pathology

• An indeterminate result often leads to additional testing and documentation

• Even negative results can signal suspected cognitive decline

• Underwriters assess the existence of testing, not just the outcome

Because of this, consumers are frequently declined before symptoms ever interfere with daily life.

Alzheimer’s Blood Tests and Long-Term Care Insurance: What Consumers Should Do First

If you want long-term care insurance and are considering testing:

1. Speak with a long-term care insurance specialist
   Review your health history before ordering new tests.

2. Apply for long-term care insurance
   Complete underwriting and secure coverage.

3. Pursue Alzheimer’s testing afterward
   Once coverage is in force, testing decisions won’t affect eligibility.

If you already had Alzheimer’s blood testing or genetic testing:

1. Obtain copies of all test results and physician notes

2. Work with an LTC insurance specialist experienced in cognitive underwriting

3. Answer application questions truthfully and accurately

If you are considering genetic testing:

1. Secure long-term care insurance first

2. Use genetic counseling before testing

3. Understand that results ordered through a physician typically enter medical records

Alzheimer’s Blood Tests and Long-Term Care Insurance: A Final Consumer Warning

Alzheimer’s blood tests represent real progress in medicine—but insurance underwriting is conservative and documentation-driven.

If protecting future care choices matters to you, the safest strategy is clear:

Secure long-term care insurance before pursuing Alzheimer’s blood tests or genetic testing for dementia.

Once testing is documented, options may be permanently limited.

Need help navigating Alzheimer’s Blood Tests and Long-Term Care Insurance?

A licensed long-term care insurance specialist can help you understand eligibility, timing, and coverage options before testing decisions are made—so you can protect both your health and your financial future.